Temporal dynamics of RSV shedding and genetic diversity in adults during the COVID-19 pandemic in a French hospital, early 2021

Coppée, Romain; Chenane, Houssem Redha; Bridier‐Nahmias, Antoine; Tchérakian, Colas; Catherinot, Émilie; Collin, Gilles; Lebourgeois, Samuel; Visseaux, Benoît; Descamps, Diane; Vasse, Marc; Farfour, Éric

doi:10.1016/j.virusres.2022.198950

Cited by 9 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Respiratory syncytial virus (RSV) is a common viral pathogen that causes 64 million acute respiratory infections annually 1 . RSV is considered as a major cause of lower respiratory tract infections among young children, elderly and immunocompromised adults worldwide, 2–5 and is a frequent cause of hospitalization 6,7 . In a recent systematic analysis, it was associated with 6.6 million acute lower respiratory infections, where more than 1 million were hospitalized and 10 000 dead in the hospital 8 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Respiratory syncytial virus incidence and typing in the last six seasons in the north of Spain (Asturias). Genetic characterization during the SARS‐CoV‐2 pandemic

Rojo‐Alba,

Martínez,

González‐Alba

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Respiratory syncytial virus is associated with lower respiratory tract infections. As several types and genotypes can circulate at the same time, genomic characterization is important for timely epidemiological control and treatment measures. In the last 6 seasons (2017–2023), 191 236 nasopharyngeal swabs were processed for respiratory viruses to determine the etiology of acute respiratory infections, describe the incidence and distribution of RSV types and enrich the data of epidemiological molecular studies on RSV in Spain. The incidence of RSV reached 7% in the pre‐pandemic season. RSV was most frequent in children under 5 years of age (12.6%), but was also significant in those over 70 years of age (5.63%). The measures taken to control SARS‐CoV‐2 infection were useful for RSV control and the incidence decreased to 1.8%, but caused a change in the types. Pre‐pandemic, the majority circulating types were RSV‐B/RSV‐B/RSV‐A and in the pandemic it was RSV‐B/RSV‐B. In the last season, RSV‐B and RSV‐A were detected in the same proportion. Genetic characterization showed three new clades. This has been taken into account to understand the epidemiology as well as the development of therapeutic and preventive strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

“…13 No effective therapy or vaccine is available to date, but vaccine candidates and monoclonal antibodies are in late clinical development. 5 Lately, a new monoclonal antibody (nirsevimab) has been approved. 14,15 The effectiveness of these therapies may vary depending on the type of virus.…”

mentioning

confidence: 99%

Respiratory syncytial virus incidence and typing in the last six seasons in the north of Spain (Asturias). Genetic characterization during the SARS‐CoV‐2 pandemic

Rojo‐Alba,

Martínez,

González‐Alba

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…For each outbreak, it is postulated that only a single genetic lineage survived the genetic bottleneck introduced by NPIs, enabling RSV activity to surge post lifting of NPIs [8 ▪▪ ]. Experts report that the resurgence is more likely explained by prolonged unreported circulation rather than the emergence of an unreported variant as the detected strains have been spreading for more than a decade [21].…”

Section: The Changing Seasonality and Molecular Epidemiology Of Respi...mentioning

confidence: 99%

Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19

Rice,

Oakes,

Holland

et al. 2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Respiratory syncytial virus (RSV) remains a leading cause of mortality and morbidity worldwide. RSV seasonality was disrupted by COVID-19-associated nonpharmaceutical interventions (NPIs). We review RSV seasonality, molecular epidemiology, clinical manifestations, and community awareness to inform future prevention strategies. Recent findings An initial reduction of RSV disease observed with NPIs, and subsequent global resurgence was associated with a collapse in genetic diversity. A lack of immunity is suggested to have contributed to the resurgence of RSV cases experienced post COVID-19. The median age of children admitted with RSV increased during the resurgence, likely secondary to the expanded cohort of RSV-immune naive children. The pandemic also played a role in increased community awareness, which can be utilized as part of a coordinated public health effort to introduce prevention strategies. Further education on signs and symptoms of RSV is still required. Summary mAbs and maternal vaccines targeting RSV have the potential to reduce paediatric morbidity, however this new era of RSV prevention will require ongoing research to facilitate community awareness and engagement, and better respiratory surveillance. Tackling the global burden of RSV will require a coordinated effort and measures to ensure access and affordability of new prevention strategies.

show abstract

“…Respiratory Syncytial Virus (RSV) is a common viral pathogen that causes 64 million acute respiratory infections annually 1 . RSV is considered as a major cause of lower respiratory tract infections amongst young children, elderly and immunocompromised adults worldwide [2][3][4][5] , and is a frequent cause of hospitalization 6,7 . In a recent systematic analysis, it was associated to 6.6 million of acute lower respiratory infection, where more than 1 million were hospitalized and 10000 dead in the hospital 8 .…”

Section: Introductionmentioning

confidence: 99%

“…No effective therapy or vaccine is available to date, but vaccine candidates and monoclonal antibodies are in late clinical development 5 . Lately, a new monoclonal antibody (nirsevimab) has been approved 13,14 .…”

Section: Introductionmentioning

confidence: 99%

Respiratory Syncytial Virus incidence and typing in the last 6 seasons in the north of Spain (Asturias). Genetic characterization during the SARS-Cov-2 pandemic

melon,

Rojo,

Pérez-Martínez

et al. 2023

Preprint

View full text Add to dashboard Cite

Respiratory syncytial virus is associated with lower respiratory tract infections. As several types and genotypes can circulate at the same time, genomic characterisation is important for timely epidemiological control and treatment measures. In the last 6 seasons (2017-2023), 191236 nasopharyngeal swabs were processed for respiratory viruses. The incidence of RSV reached 7% in the pre-pandemic season. RSV was most frequent in children under 5 years of age (12.6%), but was also significant in those over 70 years of age (5.63%). The measures taken to control SARS-Cov2 infection were useful for RSV control and the incidence decreased to 1.8%, but caused a change in the types. Pre-pandemic, the majority circulating types were RSV-B/RSV-B/RSV-A and in pandemic it was RSV-B/RSV-B. In the last season, RSV-B and RSV-A were detected in the same proportion. Genetic characterization showed three new clades. This has been taken into account in order to take the correct measures.

show abstract

Temporal dynamics of RSV shedding and genetic diversity in adults during the COVID-19 pandemic in a French hospital, early 2021

Cited by 9 publications

References 23 publications

Respiratory syncytial virus incidence and typing in the last six seasons in the north of Spain (Asturias). Genetic characterization during the SARS‐CoV‐2 pandemic

Respiratory syncytial virus incidence and typing in the last six seasons in the north of Spain (Asturias). Genetic characterization during the SARS‐CoV‐2 pandemic

Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19

Respiratory Syncytial Virus incidence and typing in the last 6 seasons in the north of Spain (Asturias). Genetic characterization during the SARS-Cov-2 pandemic

Contact Info

Product

Resources

About